FINWIRES · TerminalLIVE
FINWIRES

Zoom Communications to Gain From AI, Enterprise Growth Despite Online Pressure, RBC Says

By

Zoom Communications (ZM) could benefit from stronger enterprise demand, wider AI use, product expansion and more customers moving away from older communications systems, while slower online growth and near-term margin pressure remain risks to watch, RBC Capital Markets said in a note Tuesday.

According to the note, the company's enterprise business could keep improving as the company sells more products, moves further into larger customers, expands its sales channels and reduces customer losses.

Zoom could also win more business as companies replace older on-premise phone systems, with nine of its 10 largest phone deals in fiscal Q2 involving customers moving away from such systems to Zoom's AI services, the note said.

Online revenue remains a key concern because more customers are using AI tools instead of traditional search, while pricing comparisons and less help from foreign exchange could add pressure in H2, according to the note.

RBC maintained its outperform rating on Zoom and its $130 price target, saying that it expects costs tied to AI trials and the Common Room acquisitions to ease over time, while Zoom's technology setup and wider product use could support gross margins near its long-term 80% goal.

Price: $93.66, Change: $-7.27, Percent Change: -7.20%

Related Articles

Wire

Update: Worley Fiscal 2026 Underlying EPS, Aggregated Revenue Down; Shares Hit Six-Year Low

(Updates to add stock movement in the headline and the last paragraph.)Worley (ASX:WOR) logged AU$0.782 in underlying earnings per basic share for fiscal 2026, compared with AU$0.902 a year ago, a Wednesday filing showed.Analysts polled by FactSet expected AU$0.77.For the 12 months ended June 30, aggregated revenue was AU$12.02 billion versus AU$12.05 billion previously, the Australia-listed provider of engineering and project delivery services added. Analysts surveyed by FactSet projected AU$11.73 billion.The board proposed a final dividend of AU$0.25 per share, unchanged from a year earlier, payable Sept. 30 to shareholders of record as of Sept. 2.The company guided for fiscal 2027 underlying earnings before interest, taxes, and amortization growth, and for aggregated revenue growth, in the mid-to-high single-digit range.Its shares fell nearly 11% in recent trading on Wednesday and earlier hit their lowest since August 2020.

ASX:WOR
Wire

Update: HEICO Fiscal Q3 Earnings, Revenue Rise

(Updates to add share movement in the fifth paragraph.)HEICO (HEI) reported late Tuesday a fiscal Q3 earnings of $1.67 per diluted share, up from $1.26 a year earlier.Analysts polled by FactSet expected $1.51.Revenue for the quarter ended July 31 was $1.41 billion, up from $1.15 billion a year ago.Analysts expected $1.35 billion.Shares of the company rose 2.5% in after-hours trading.

$HEI
Wire

Spyre Halts Stand-Alone Rheumatoid Arthritis Drug Development; Shares Fall After Hours

Spyre Therapeutics (SYRE) said its experimental rheumatoid arthritis drug SPY072 failed to meet the company's internal performance threshold needed to justify further stand-alone development, prompting the halt of its monotherapy RA program.The drug delivered statistically significant improvements over placebo on several efficacy measures and showed a tolerable safety profile with no drug-related serious adverse events, the company said Tuesday in a statement.Spyre said it will now evaluate SPY072 in combination regimens and in other autoimmune indications, with additional clinical readouts expected in Q4.Spyre shares fell 12% in after-hours trading.

$SYRE